Fair value, page-60

H, maybe the recently launched Car-T Cell programme is setting up the de-risking play, but without throwing another baby out with the bath water.

I'm in preference of this as a de-risking strategy, as signing off another promising but unproven in human programme (eg: pain programme) doesn't have enough return.

As Car-T is rapidly becoming a hot area, as Max and Panno have pointed out, and has proven clinical results by Carl J, it may well be able to be dealt out prior to in house clinical results.

http://www.fiercebiotech.com/story/...car-t-tech-after-banking-65m-round/2015-06-11